Guideline and policy registry — hypertensive heart disease¶
Last curated: 2026-08-31. This is a navigation and comparison register, not a substitute for the source documents. Every PMID below was resolved through live PubMed E-utilities in this build session. “HHD coverage” distinguishes direct recommendations from hypertension or heart-failure recommendations applied to HHD by inference.
Current core guidance¶
| Jurisdiction / body | Document | Year | PMID | HHD coverage | Current role |
|---|---|---|---|---|---|
| United States — AHA/ACC and partners | High Blood Pressure in Adults guideline | 2025 | 40815242 | Mostly indirect: BP diagnosis, risk, targets, treatment | Current U.S. hypertension anchor |
| Europe — ESC | Elevated Blood Pressure and Hypertension guideline | 2024 | 39210715 | Mostly indirect; organ damage affects risk | Current ESC hypertension anchor |
| Europe — ESH | Arterial Hypertension guideline | 2023 | 37345492 | Hypertension-mediated organ damage is explicit | Current ESH full guideline |
| Europe — ESH | Clinical-practice recommendations | 2024 | 38914505 | Operational companion | Implementation aid |
| Global — WHO | Pharmacological treatment of hypertension in adults | 2021 | 34775787 | Indirect; treatment initiation and delivery | Resource-sensitive global standard |
| Global — ISH | Global Hypertension Practice Guidelines | 2020 | 32370572 | Essential and optimal standards; organ damage | Global pragmatic framework |
| United Kingdom — NICE | Hypertension in adults: diagnosis and management | 2019 update summary | 31636059 | Indirect; ABPM/HBPM and treatment pathway | UK primary-care anchor |
| Canada — Hypertension Canada | Adult hypertension guideline | 2025 | 40419299 | Indirect; risk-based diagnosis and treatment | Current Canadian anchor |
| Japan — Japanese Society of Hypertension | JSH 2019 highlights | 2020 | 31891452 | Indirect; Asian population context | National hypertension guidance |
| United States — AHA/ACC/HFSA | Heart failure management guideline | 2022 | 35363499 | Direct after clinical HF develops | HFrEF/HFpEF treatment anchor |
| Europe — ESC | Heart failure management guideline | 2026 | 42661420 | Direct after clinical HF develops | Current European HF anchor; text not yet read into this build |
| Europe — ESC / ERA | Cardiovascular disease and chronic kidney disease guideline | 2026 | 42661426 | Indirect: CKD constrains BP targets and RAAS/MRA safety in HHD | New document; text not yet read into this build |
| Europe — ESC | Acute and chronic heart failure guideline | 2021 | 34447992 | Direct after clinical HF develops | Superseded by the 2026 ESC HF guideline; still the source of every ESC HF statement currently in this build |
| United States — ACC/AHA/ACCP/HRS | Atrial fibrillation guideline | 2023/2024 | 38033089 | Direct for AF complication; HHD is substrate | AF diagnosis, stroke and rhythm pathway |
| Endocrine Society | Primary aldosteronism guideline | 2025 | 40658480 | Direct for a high-yield secondary cause | Screening and specific treatment |
| Pan-African Society of Cardiology | ISH-guideline commentary | 2020 | 33404583 | Implementation and access context | Regional translation |
| South Africa | Hypertension guideline implementation analysis | 2024 | 39494661 | Health-system implementation context | National/regional gap analysis |
What the major documents actually govern¶
| Clinical decision | Primary sources | What is stable | What remains HHD-specific and unsettled |
|---|---|---|---|
| Confirming hypertension | NICE 2019; ESC 2024; AHA/ACC 2025 | Repeat standardized measurements; use out-of-office confirmation when feasible | No consensus on which ambulatory metric best tracks myocardial remodeling |
| Treatment initiation | WHO 2021; ISH 2020; national guidance | Combine BP level, established CVD, comorbidity, and absolute risk | Whether imaging-only LVH/fibrosis should independently trigger a different regimen |
| BP target | ESC 2024; AHA/ACC 2025; ESH 2023 | Lower is generally better when measured correctly and tolerated | No randomized target specifically for imaging-defined HHD |
| First-line drug class | WHO 2021; AHA/ACC 2025; ESC/ESH | Thiazide-type diuretic, ACEi/ARB, or long-acting dihydropyridine CCB are core choices | Whether CMR fibrosis or geometry should choose among classes |
| Resistant hypertension | ESH 2023; AHA/ACC 2025 | Confirm true resistance, optimize diuretic therapy, consider MRA | Best sequence in advanced CKD and whether HHD phenotype predicts response |
| Secondary causes | Hypertension guidelines; Endocrine Society 2025 | Investigate when clinical pattern or resistance raises probability | Optimal breadth of testing in established remodeling |
| LVH assessment | ESC/ESH and ISH | ECG is accessible; echo is more sensitive and can change risk classification | Routine screening intervals and CMR escalation thresholds |
| HFpEF treatment | AHA/ACC/HFSA 2022; ESC 2021 plus updates | Treat congestion and comorbidities; use outcome-proven HF therapy | Whether pre-HF HHD warrants HF drugs before symptoms |
| HFrEF treatment | AHA/ACC/HFSA 2022; ESC 2021 | Rapid, tolerated use of foundational disease-modifying therapy | How to distinguish hypertensive attribution from ischemic or valvular cause |
| AF and stroke prevention | ACC/AHA/ACCP/HRS 2023 | Anticoagulation follows validated thromboembolic risk; control BP | No HHD-specific anticoagulation threshold |
| Pregnancy | National obstetric/hypertension guidance | Severe hypertension needs urgent treatment; teratogenic drugs must be avoided | Sparse evidence for women entering pregnancy with established HHD |
Threshold and target comparison¶
Guidelines use different measurement conventions and risk frameworks. Numerical thresholds should never be compared without the measurement method.
| Framework | Diagnostic / treatment emphasis | General treatment target framing | Important qualifiers |
|---|---|---|---|
| AHA/ACC 2025 (PMID 40815242) | Risk-based treatment with stage-based BP categories | Generally <130/80 mm Hg for treated adults where appropriate | Standardized measurement, comorbidities, tolerability |
| ESC 2024 (PMID 39210715) | Introduces “elevated BP” and retains hypertension threshold; emphasizes CVD risk | On-treatment systolic 120–129 mm Hg for many adults if tolerated | Opt-out for intolerance, frailty, limited life expectancy and orthostatic symptoms |
| ESH 2023 (PMID 37345492) | Office BP plus out-of-office confirmation; explicit HMOD assessment | Initial control below 140/90, then lower individualized targets | Age, comorbidity and treatment tolerance |
| WHO 2021 (PMID 34775787) | Scalable initiation, drug combinations and follow-up | Pragmatic population treatment standard | Resource availability and implementation feasibility |
| ISH 2020 (PMID 32370572) | Essential versus optimal standards | Stepwise targets and treatment | Designed for diverse resource settings |
| NICE summary (PMID 31636059) | ABPM/HBPM confirmation and age-stratified targets | Clinic and home/ambulatory targets differ | Frailty, postural hypotension and type 2 diabetes pathways |
| Canada 2025 (PMID 40419299) | Risk-based diagnosis and treatment | Intensive systolic target for suitable adults | Requires standardized automated measurement and suitability |
Measurement non-equivalence¶
| Measurement | Why the number differs | Guideline implication |
|---|---|---|
| Routine office BP | Observer, rest, talking, cuff and digit preference affect result | Do not map trial targets blindly onto casual readings |
| Standardized automated office BP | Rest and automation can yield lower, more reproducible values | Closest to some intensive-target trials |
| Home BP | Multiple days capture usual environment | Useful for confirmation and titration |
| Daytime ambulatory BP | Captures activity-period load | Detects white-coat and masked hypertension |
| Nighttime ambulatory BP | Captures sleep pressure and dipping | Adds risk information; sleep quality and schedule matter |
| 24-hour ambulatory BP | Weighted day/night average | Best single summary of sustained load, but access is unequal |
Guideline-by-guideline notes¶
AHA/ACC 2025¶
- Citation: Jones DW, et al. 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. PMID 40815242.
- Replaces the 2017 U.S. guideline (PMID 29133356).
- HHD is handled primarily as hypertension-mediated target-organ disease and through clinical syndromes, rather than as one operational diagnostic entity.
- Best use here: U.S. BP definitions, treatment logic, target framing, and comorbidity-specific management.
ESC 2024¶
- Citation: McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. PMID 39210715.
- Separates “elevated BP” from hypertension and emphasizes cardiovascular-risk reduction.
- Best use here: European target framework, out-of-office measurement, and risk modifiers.
- Must be read beside rather than conflated with the separate 2023 ESH guideline.
ESH 2023 and practice recommendations 2024¶
- Full guideline: PMID 37345492.
- Clinical-practice recommendations: PMID 38914505.
- “Hypertension-mediated organ damage” provides the closest guideline umbrella for preclinical HHD.
- Best use here: target-organ assessment, resistant hypertension, treatment sequence, and pragmatic application.
WHO 2021¶
- Citation: Guideline for the pharmacological treatment of hypertension in adults, PMID 34775787.
- Focuses on scalable treatment thresholds, drug selection, combinations, and follow-up.
- Best use here: minimum global delivery standard.
- It is not a cardiac-imaging guideline and does not validate an HHD phenotype algorithm.
ISH 2020¶
- Citation: Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. PMID 32370572.
- Separates essential from optimal standards so a usable pathway remains when ABPM, echo, or CMR is unavailable.
- Best use here: global implementation and a minimum phenotype.
NICE¶
- Peer-reviewed summary: Boffa RJ, et al. Hypertension in adults: summary of updated NICE guidance. PMID 31636059.
- Particularly useful for confirmation by ABPM or HBPM and age-sensitive primary-care targets.
- The live NICE document should be checked for operational updates before clinical use.
Hypertension Canada 2025¶
- Citation: PMID 40419299.
- Uses standardized measurement and cardiovascular-risk logic.
- Best use here: a contemporary national contrast to U.S. and European frameworks.
Heart-failure guidelines¶
- U.S.: Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline, PMID 35363499.
- Europe (current): Køber L, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;:ehag100. PMID 42661420. Published 2026-08-28.
- Europe (superseded): McDonagh TA, et al. 2021 ESC HF Guideline, PMID 34447992.
- Registration status, 2026-08-31 sweep. The 2026 ESC HF record was resolved live in PubMed, but the document itself was not retrieved and no recommendation from it has been read. It is registered here as a document, not yet as a synthesized position; every ESC HF statement in
wiki/guidelines.mdandwiki/heart-failure-management.mdstill derives from the 2021 text. Re-synthesis against the 2026 document is the highest-priority guideline task for the next sweep. - These apply after a clinical HF syndrome is established. They do not independently prove that asymptomatic LVH or fibrosis should receive syndrome-level HF therapy.
Cardiovascular disease and chronic kidney disease¶
- Citation: Damman K, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J. 2026;:ehag098. PMID 42661426. Published 2026-08-28.
- Relevant because CKD is simultaneously an HHD risk amplifier and the main constraint on RAAS blockade, MRA use and intensive BP targets.
- Same registration status as above: record resolved live, text not read, no recommendation asserted.
- A related implementation document — the KDIGO Asia-Pacific summit report on implementing the KDIGO diabetes (2022) and BP-in-CKD (2020) guidelines — is a barriers-and-solutions conference report rather than a guideline, and is catalogued in the bibliography only (Yee-Moon Wang 2026, PMID 42660227).
Atrial-fibrillation guideline¶
- Citation: Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline, PMID 38033089.
- Applies to AF emerging on the HHD substrate: stroke prevention, rate/rhythm control, risk-factor management, and ablation decisions.
- HHD itself does not replace validated thromboembolic-risk assessment.
Primary aldosteronism¶
- Citation: Endocrine Society Clinical Practice Guideline, PMID 40658480.
- Relevant because aldosterone excess produces disproportionate cardiovascular and renal injury and is specifically treatable.
- Screening is a secondary-hypertension decision, not a universal biomarker test for HHD.
Material disagreements¶
| Issue | Positions that differ | Practical reconciliation |
|---|---|---|
| Hypertension threshold | U.S. categories begin lower than traditional European diagnostic hypertension threshold | Record exact BP and method; do not communicate only the label |
| Treatment target | U.S., ESC, ESH, NICE and Canada frame intensity differently | Translate to standardized measurement, absolute risk, and tolerability |
| Routine organ-damage testing | Extent of ECG, urine, echo and vascular testing varies | Test when result changes risk, diagnosis, or treatment |
| Beta-blocker placement | Generally not first-line without indication, but details vary | Use when compelling indication exists; LIFE is not a universal beta-blocker prohibition |
| Initial combination therapy | Broadly favored at higher BP, with differences in thresholds and exceptions | Account for frailty, orthostasis, baseline BP and adherence |
| Resistant-hypertension sequence | MRA strongly supported, but CKD/potassium constraints differ | Confirm pseudo-resistance and monitor kidney function/potassium |
Superseded chains¶
| Earlier document | PMID | Successor / current comparator | PMID |
|---|---|---|---|
| 2017 ACC/AHA High BP guideline | 29133356 | 2025 AHA/ACC High BP guideline | 40815242 |
| 2018 ESC/ESH hypertension guideline | 30165516 | 2024 ESC guideline and 2023 ESH guideline | 39210715; 37345492 |
| Earlier U.S. HF guidance | — | 2022 AHA/ACC/HFSA HF guideline | 35363499 |
| Earlier ESC HF guidance | — | 2021 ESC HF guideline | 34447992 |
| 2021 ESC HF guideline | 34447992 | 2026 ESC HF guideline | 42661420 |
Evidence gaps not resolved by any guideline¶
- A reproducible clinical definition separating HHD from hypertension plus coincidental cardiac disease.
- A randomized test of imaging- or biomarker-triggered therapy versus risk-based BP treatment.
- A validated schedule for repeat echo or CMR in asymptomatic hypertension.
- A treatment target for LV mass, GLS, ECV, or interstitial fibrosis volume.
- Cross-platform and cross-ancestry calibration of emerging biomarker staging.
- A minimum HHD dataset feasible across low-, middle-, and high-resource settings.
- Explicit patient-reported outcomes for asymptomatic organ-damage labeling.
- Guidance for de-labeling when BP normalizes or remodeling regresses.
Watch list¶
| Topic | Signal to watch | Why it could change this build |
|---|---|---|
| Biomarker staging | External validation of REMODEL thresholds | Could create a reproducible preclinical staging layer |
| Treat-to-regression trials | Clinical endpoints tied to serial CMR/echo | Could make remodeling actionable |
| Renal denervation | Durable sham-controlled outcomes and event trials | Could alter resistant-hypertension pathways |
| Primary aldosteronism | Broader screening and outcome-guided treatment | Could reclassify a substantial secondary subgroup |
| HFpEF prevention | Trials before symptomatic HF | Could connect HHD phenotype to syndrome prevention |
| Global implementation | Fixed-dose combinations and community delivery | Could reduce HHD burden more than advanced imaging |
| 2026 ESC HF and CKD guidelines | Whether stage-B/pre-HF criteria become imaging- or biomarker-based, and whether CKD BP/RAAS boundaries move | Would change the HHD prevention and safety framing directly (PMIDs 42661420; 42661426) |